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INTRODUCTION 
Whilst molecular markers are being used more frequently to select patients for 
systemic targeted agents, only imaging modalities are used to stage patients and 
assess suitability for operative resection. Decisions on primary surgery, or a 
neoadjuvant approach are made without biological measures of tumor 
aggressiveness, or the risk of occult metastatic disease. This is exemplified in 
pancreatic ductal adenocarcinoma (PDAC), which has overtaken breast cancer to 
become the third most common cause of cancer death in the USA.1 Surgical resection 
offers the only chance of cure, with chemotherapy adding modest benefit, but surgery 
can be associated with significant morbidity and mortality risk. Even with complete 
resection and adjuvant chemotherapy, the five-year survival rate is only ~20%2-6, with 
~30% succumbing within the first year (mostly due to distant metastatic disease).7, 8 
This high metastatic recurrence rate indicates current staging modalities for PDAC 
cannot identify patients with occult metastases and aggressive biology. For these 
patients, surgical resection brings uncertain benefit. Whipple’s 
pancreaticoduodenectomy can be associated with significant mortality risk and 
morbidity that leads to long post-operative recovery periods of 3-6 months, which 
presents significant implications on patients’ quality of life9. Hence, better selection 
methods are urgently needed. 
 
Prognosis prediction tools such as nomograms have been developed for many cancer 
types to better inform treatment decisions. The most widely used tool in resectable 
PDAC is the prognostic nomogram developed at the Memorial Sloan-Kettering Cancer 
Centre (MSKCC).10,11-13 However, these can only be applied after resection as they 
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include clinicopathological variables only available following assessment of the 
resected specimen.  
 
Numerous molecular biomarkers with potential clinical utility have been studied in 
PDAC, but few have been independently validated.14-16 Our group and others have 
demonstrated that aberrant expression of S100A2 and S100A4 calcium-binding 
proteins, both of which function to accentuate tumor aggressiveness and metastasis, 
are associated with poor survival in PDAC.17-19 Using RNA sequencing and 
methylation arrays, we recently reported hypomethylation of S100A2 is associated with 
the prognostic ‘Squamous’ subtype of PDAC.20  This poor prognostic subtype is 
consistently defined in molecular classifications of PDAC (also termed Quasi-
Mesenchymal21 or Basal22) and S100A2 remains a highly significant gene in each 
classifier.20-22 
 
Here, we assess and validate the prognostic value of these two molecules in 1184 
patients. Aberrant expression of these biomarkers stratify patients with resectable 
pancreatic cancer into three distinct prognostic groups in a training set (n = 518) and 
form the basis of a biomarker-based pre-operative nomogram aimed at identifying 
those at high risk of early recurrence. This nomogram was validated in two further 
cohorts (n = 198 and 468), and the proof-of-concept feasibility of its pre-operative use 
was assessed using pre-operative endoscopic ultrasound fine-needle aspiration 
biopsies (EUS-FNA). 
 
METHODS 
Patients and Tissue Specimens 
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Detailed clinicopathological and outcome data were obtained for three cohorts of 
consecutive unselected patients, totaling 1184, with primarily resected PDAC (Figure 
1). None of the patients received neoadjuvant chemo- or radiotherapy. The training 
cohort of 518 patients were accrued prospectively through the Australian Pancreatic 
Cancer Genome Initiative (APGI) (www.pancreaticcancer.net.au), for the International 
Cancer Genome Consortium (ICGC; www.icgc.org).23 The two independent validation 
cohorts of 198 and 468 patients were from the West of Scotland Pancreatic unit, 
Glasgow Royal Infirmary, United Kingdom; and the Technical University of Dresden, 
Dresden, Germany respectively (Table 1). Some patients from these cohorts were 
used for previous studies.19, 20, 24-29 The current study was conducted in accordance 
with the TRIPOD Type 3 model development approach, and REMARK (Reporting 
Recommendations for Tumor Marker Prognostic Studies) criteria (Supplementary 
Material).30 All patients were treated after 1998 with more modern approaches such as 
multi-modality therapy, and some were part of Phase III randomized-controlled trials 
such as ESPAC-3.2 All cohorts displayed clinical and pathological features consistent 
with the behavior of PDAC and are similar to published PDAC cohorts worldwide.31, 32 
The diagnosis and all pathological features were reviewed centrally by at least one 
specialist pancreatic histopathologist, and the date and cause of death was obtained 
from Central Cancer Registries or treating clinicians. RNA sequencing data was 
generated as part of the APGI’s contribution to the ICGC, and sample processing and 
data analysis was performed as previously described.20  
 
Ethical Statement  
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Ethical approval for the acquisition of data and biological material was obtained from 
the Human Research Ethics Committee at each participating institution 
(Supplementary Material).  
 
Tissue Microarray & Immunohistochemistry  
Detailed methods for tissue microarray (TMA) construction and immunostaining 
assessment were described previously.33 In brief, immunostaining on resection 
specimens were performed using  TMAs constructed from 3 distinct areas per tumor. 
TMA sections were incubated with anti-S100A2 mouse monoclonal antibody, 1:50 
dilution, (clone DAK-S100A2/1; Dako Corporation, Glostrup, Denmark) and anti-
S100A4 rabbit polyclonal antibody (NeoMarkers, Cat. #RB-1804, Fremont, CA, USA) 
with a dilution of 1:100 for 60 minutes. As part of a standardized biomarker 
discovery and development process, initial cut-offs were generated using earlier 
training/discovery cohorts, then validated using independent validation cohorts. 
S100A2 and S100A4 expression analysis was performed in an early training 
cohort of PC to define the optimal expression for analysis.19 High S100A2 
expression was defined as cytoplasmic staining with intensity 3+ in >30% of cells and 
positive S100A4 expression was defined as either nuclear and/or cytoplasmic staining 
of any intensity in > 1% of cells.19 Aberrant expression of S100A2 and S100A4 were 
correlated to survival after pancreatectomy. 
 
Statistical Analysis 
The influence of clinicopathological variables on survival was assessed with Cox 
proportional hazards regression, and the differences in outcome between predefined 
subgroups was evaluated using the log-rank test.34 Where multiple cohorts were 
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included in a single model, baseline hazard was always stratified by cohort throughout 
the procedure. On the basis of exploratory analysis, age was modelled with a cohort 
interaction term in the combined models; no other substantive variable to cohort 
interactions were identified. P-values of less than 0.05 were considered statistically 
significant. Statistical analysis was performed using SPSS (Version 22.0; IBM SPSS 
Statistics, IBM Corporation, Armonk, NY). Model fitting and nomogram generation was 
performed using R 3.4.0 (The R Project for Statistical Computing, Vienna, Austria). 
Disease-specific survival (DSS) was used as the primary endpoint for the APGI and 
Glasgow cohorts. Patients succumbing to other causes were right censored in the 
analysis. As the majority of patients with PDAC unfortunately succumb to disease, 
even after seemingly curative resection35, overall survival (OS) was used for the 
German cohort, as disease-specific survival was not available. 
 
Prognostic Nomograms 
MSKCC Nomogram Evaluation 
The published MSKCC nomogram10 was applied to the APGI, Glasgow, and German 
cohorts, yielding per-patient estimates of linear risk score and 6-, 12- and 24-month 
survival probabilities (Figure 1) (Supplementary Material).  Some variables in the 
MSKCC nomogram were not collected in the current cohorts and were imputed to the 
mean value of that variable reported for the MSKCC nomogram derivation cohort 
(Table S2). 
 
Nomogram Construction 
Two Cox proportional hazard models were fit to the APGI training cohort data (Figure 
1), one containing conventional clinicopathological variables available post-operatively 
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(age, tumor size, T-stage, tumor location, vascular invasion, perineural invasion, 
margin status, presence of lymph node metastases, and differentiation), and the other 
containing only variables assessable pre-operatively (age, tumor size, tumor location, 
and S100A2 and S100A4 status).  Patient sex was not included in models due to its 
known poor prognostic value in PDAC.10 To improve the clinical utility of the 
nomogram, follow-up was truncated at 24 months to focus prognosis prediction in this 
most clinically critical period following surgery.  To simplify generation and application 
of the predictive nomograms, violations of the proportional hazards assumption were 
addressed by stratifying the baseline hazard by predictive variables, rather than 
introducing interaction with a time-dependent stratum.   
 
Nomogram Testing 
Nomograms were tested for discrimination and calibration against validation cohorts 
(Glasgow and Germany) using established methods.36, 37 Variability of the Brier score 
assessment of overall fit was estimated using 5,000 bootstrap rounds.36, 37  
 
EUS-FNA and Cell Block Construction 
EUS-FNA samples were collected and processed as per the standard diagnostic 
pathway using endoscopic and cytohistological techniques according to local 
practice. Formalin-fixed EUS-FNA tissue fragments or cell block preparations were 
embedded in paraffin, sectioned (4 µm) and H&E stained as standard.  Staining for 
S100A2 and A4 were performed as described above and compared with 
corresponding resection specimen from 17 consecutive patients undergoing both 
EUS-FNA and pancreatectomy.  
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RESULTS 
Patient characteristics are summarized in Table 1, with detailed descriptions provided 
in the Supplementary Material.  
 
High S100A2 and S100A4 Expression is associated with Poor Survival after 
Pancreatectomy 
In all three cohorts, high expression of S100A2 calcium-binding protein was associated 
with poor survival after pancreatectomy. In the APGI cohort, expression of S100A2 
was high in 115 of 507 patients (22.7%) (median survival 21.0 Vs 15.0 months; P = 
0.023) (Table 1, Figure 2). S100A2 expression was high in 63 out of 198 patients 
(31.8%) in the Glasgow cohort (median survival 24.7 vs 13 months; P < 0.001) and in 
118 out of 400 patients (29.5%) in the German cohort (median survival 18.2 vs 11.9 
months; P < 0.001) (Table 1, Figure 2).  
 
High S100A2 expression remained a significant independent prognostic factor in a 
combined multivariate model of all 3 cohorts (Table 2; HR = 1.64, 95% CI 1.33 – 2.02 
P < 0.001). This was also the case in the APGI (Table S3; HR 1.32, 95% CI 0.97 – 
1.80, P < 0.001) and Glasgow (Table S4; HR 2.00, 95% CI 1.36 – 2.90, P < 0.001) 
cohorts, but not the German (Table S5; HR 1.48, 95% CI 0.95 – 2.29, P = 0.076) 
cohort. It is likely that this reflects reduced power or cohort-specific variable 
collinearities, as the influence of S100A2 expression on survival was not significantly 
different between cohorts (Likelihood ratio test, χ2 = 4.86, df = 2, P = 0.09). 
Furthermore, S100A2 was associated with poor survival in the German cohort 
(univariate cox regression (HR 1.69, 95% CI 1.34 – 2.14, P < 0.001) and log rank 
survival analysis (Figure 2C)). When considered alongside a previous study with over 
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400 (200 non-redundant) patients this provides a total of over 1300 cases supporting 
the association of high S100A2 expression and poor survival.19  
 
Positive expression of S100A4 was associated with poor survival after pancreatectomy 
in all three cohorts. In the APGI cohort, 345 out of 514 patients (67.1%) had positive 
expression of S100A4, which was associated with a significantly worse outcome 
(median survival 29.9 Vs 16.2 months; P < 0.001) (Table 1, Figure 2).  These findings 
were recapitulated in the Glasgow cohort with 137 out of 198 patients (69.2%) with 
analyzable tissue demonstrating positive expression of S100A4, that was again 
associated with poor outcome (median survival 26.4 Vs 16.2 months; P = 0.010) (Table 
1, Figure 2). In the German cohort, 288 out of 430 patients (72.0%) with positive 
S100A4 expression demonstrated significantly worse outcome (median survival 22.0 
vs 14.6 months, P = 0.013) (Table 1, Figure 2). 
 
In a combined multivariate model, S100A4 remained strongly prognostic in a time 
dependent manner with its effect on prognosis decreasing after 24 months in both the 
combined (HR 2.06, 95% CI 1.30 – 3.28, P < 0.001 at 12 months), and individual 
models (Tables 2, S3-S5). This data suggests that S100A4 is a strong predictor of 
disease recurrence in the first 24 months after surgery, with its effect decreasing after 
this period. S100A4 was an independent prognostic factor in multivariate models in the 
APGI (Table S3, HR 2.13, 95% CI 1.08 – 4.17, P = 0.018 at 12 months) and Glasgow 
(Table S5, HR 2.37, 95% CI 0.97 – 5.79, P = 0.048 at 12 months) cohorts.  Similar to 
S100A2, S100A4 was not significant in a multivariate model in the German cohort 
(Table S5), however, was predictive in univariate cox regression (HR 1.33, 95% CI 
1.06 – 1.67, P = 0.013) and log rank survival analysis (Figure 2).  
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Expression of S100A2 and S100A4 Stratifies Patients into 3 Prognostic Groups 
The combined prognostic effects of the two biomarkers were assessed independently 
in all three cohorts (Figure 1). In all three cohorts, tumors with high S100A2 
expression were more likely to be associated with positive S100A4 expression 
(Table S6 in Supplementary Material, P ≤ 0.001). In the APGI cohort, patients with 
low or no expression of either S100A2 or S100A4 had the best prognosis, followed by 
patients with either high S100A2 or positive S100A4 expression, and patients with both 
biomarkers positive had the worst prognosis (median survival 29.8 vs 17.0 vs 13.2 
months respectively, P < 0.001) (Figure 1). These findings were validated in the 
Glasgow (median survival 26.5 vs 20.1 vs 9.3 months; P < 0.001) and the German 
(median survival 22.9 vs 14.3 vs 12.9 months; P < 0.001) cohorts (Figure 1). When 
combining all 3 cohorts, patients with both biomarkers positive had a 12-month survival 
rate of only 54% after pancreatectomy, compared to 79% and 66% in the biomarker 
negative or single biomarker positive groups respectively (P < 0.001) (Figure 1).  
There was no difference in the use of adjuvant chemotherapy between patients 
who were biomarker negative and those with a single biomarker positive in all 
three cohorts (Table S7 in Supplementary Material). In the APGI cohort, patients 
with both biomarkers positive had lower adjuvant therapy use rate (Table S7, P 
= 0.025). There were no significant differences in adjuvant therapy use amongst 
biomarker groups in the Glasgow and German cohorts (Table S7 in 
Supplementary Material). 
 
Expression of S100A2 and S100A4 co-segregates with the Squamous subtype 
of PDAC  
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In 96 patients who underwent whole transcriptome sequencing analysis as part of the 
APGI (ICGC) cohort, S100A2 and S100A4 mRNA expression was significantly 
associated with the recently described squamous subtype20 (P < 0.01; Figure 3, Table 
S8 in Supplementary Material). This was recapitulated in the 235 patients who 
underwent micro-array mRNA expression analysis, as described by Bailey et al.20 
Using both mRNA and protein expression, patients with high S100A2 (P = 0.002) and 
positive S100A4 (P < 0.001) expression were associated with the squamous subtype, 
with the strongest correlation in those with both biomarkers positive (Figure 3, Table 
S9 in Supplementary Material). Squamous subtype tumors20 were associated with a 
significantly higher mean nomogram score than other subtypes (140 vs 103; P = 
0.004).   
 
MSKCC Prognostic Nomogram Validation for Resectable PDAC 
After demonstrating the association of S100A2 and S100A4 expression with the pro-
metastatic squamous subtype and poor prognosis in PDAC, the potential clinical utility 
of a prognostic nomogram incorporating molecular biomarkers was explored. The 
overall fit of the published MSKCC nomogram to all three cohorts was assessed by 
stratifying patients using predicted survival score and comparing observed and 
MSKCC predicted survival (Figure 1D(i)). Relative to the true outcome, MSKCC 
nomogram predictions were optimistic, particularly at later time points, this was 
especially true for the German cohort (Figure S1, Supplementary Material). The 
MSKCC nomogram risk score was prognostic in the APGI and Glasgow cohorts (Cox 
regression coefficients 0.79 and 1.35, likelihood ratio test for coefficient not zero, P = 
5.0 x 10-5 and 0.025, respectively), but not the German cohort (coefficient 0.15, P = 
0.31). The MSKCC risk score was well-calibrated against the APGI and Glasgow 
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cohorts (Likelihood-ratio test for coefficient not unity, P = 0.28 and 0.56, respectively), 
but less well against the German cohort (P = 2.6 x 10-9) (Figures 1D(ii) and S1, 
Supplementary Material). 
 
Pre-Operative Molecular Nomogram Predicts Survival after Pancreatectomy as 
accurately as Post-Operative Clinicopathological Nomogram  
A molecular nomogram incorporating S100A2 and S100A4 expression was then 
constructed. The APGI cohort was used to construct two prognostic nomograms based 
on the Cox proportional hazards model: one employing traditional post-operatively 
available variables (“Post-operative Prognostic Nomogram”) (Figures 1E(iii) and S2, 
Supplementary Material), and one employing only variables that can be measured pre-
operatively (“Pre-operative Prognostic Nomogram”) (Figures 1E(iv) and 4). To improve 
the clinical utility of predicting early recurrence and to incorporate the prognostic value 
of S100A4 over the initial 24 months following surgery, follow-up was truncated at 24 
months. Both models included tumor location (pancreatic head vs body / tail), after 
exploratory analysis in the APGI cohort indicated differences in baseline hazard 
between these patient groups (Table S10, Supplementary Material).38  
 
Risk stratification accuracy of the APGI pre-operative and APGI post-operative 
nomograms were assessed in the Glasgow and German validation cohorts. The pre-
operative prognostic nomogram displayed good discrimination on both validation 
cohorts (risk score Cox coefficients 0.59 and 0.66, P = 1.7 x 10-3 and 1.2 x 10-5 for 
Glasgow and German respectively) (Figure 1E(v)).  Notably, the APGI pre-operative 
nomogram was superior to the MSKCC post-operative prognostic nomogram in both 
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its spread of risk scores, and the accuracy of its absolute survival estimates (Figures 
S1 and S3, Supplementary Material). 
 
The overall accuracy of the APGI pre-operative nomogram in predicting patient survival 
was assessed and compared to the APGI post-operative nomogram. Although the pre-
operative nomogram was slightly optimistic by predicting marginally better outcome 
probabilities than those observed in the Glasgow and German cohorts, it was more 
accurate than the MSKCC post-operative nomogram (Figures S1 and S3, 
Supplementary Material).  Brier scores was used to formally evaluate the relative 
performance of the APGI pre-operative and post-operative nomograms with over 5,000 
bootstrap draws of each validation cohort. This demonstrated the APGI pre-operative 
nomogram was more accurate than the MSKCC post-operative nomogram, and as 
accurate as the APGI post-operative nomogram in outcome predictions (Figures S4 
and S5, Supplementary Material). 
 
Pre-operative Assessment of Biomarker Expression in EUS-FNA Samples 
A pilot study was performed on 17 consecutive patients to compare biomarker 
expression status between pre-operative EUS-FNA cell blocks and the corresponding 
surgical resection specimen (Table S11, Supplementary Material). S100A2 and 
S100A4 expression correlated in 15 (88%) and 14 (82%) out of 17 patients 
respectively, based on the EUS-FNA cell block and the surgical specimen for both 
biomarkers examined (representative images are shown in Figure 5). This 
demonstrates that biomarker status can be measured pre-operatively using 
immunohistochemistry, and it is likely that EUS biopsy assessment will improve with 
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the current development of more effective biopsy needles and standardization of 
processing techniques. 
 
DISCUSSION 
Despite our increasing understanding of the molecular heterogeneity in 
morphologically identical cancers, and the advances in molecularly guided targeted 
therapy selection, the impact of these findings in surgical decision-making has not 
been addressed. Perioperative mortality for pancreatectomy has improved 
dramatically over the last 30 years and the definition of “resectability” has been 
expanded over the last decade with increasingly aggressive surgery being 
performed.39, 40 However, early recurrence remains the Achilles’ heel of surgical 
resection, making better patient selection for surgery a priority area of research.  
 
In this study, the expression of two molecules, S100A2 and S100A4, which functionally 
promote carcinogenesis and metastasis, were validated as prognostic biomarkers in 
multiple independent cohorts of patients with resectable PDAC (n = 1184), in keeping 
with earlier studies (n = ~400).19 These two biomarkers were used to stratify patients 
with resectable PDAC into distinct prognostic phenotypes after pancreatectomy. 
Patients with both biomarkers positive are at significant risk of early recurrence, with 
almost half of these patients succumbing within 12 months after pancreatectomy (12-
month survival rate = 54%). Suggesting that disease recurrence occur at around 6 
months or earlier for the majority of this group. The risk and pattern of disease 
recurrence following pancreatectomy is not proportional and early recurrence 
has recently been defined as within 12 months following surgery.35, 41 We focused 
on outcome in the first 24 months post-operatively for nomogram construction since 
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the majority of patients that develop early recurrence will succumb to the disease by 
this point, and thus improve its clinical utility.41 A pre-operative prognostic nomogram 
incorporating these two biomarkers, and pre-operatively determined variables 
including age, tumor size and location was developed and independently validated. 
This pre-operative prognostic nomogram performed as well as the published MSKCC 
post-operative prognostic nomogram, which is the most widely used, and currently 
considered the gold standard. In our study, a number of variables used in the MSKCC 
nomogram was missing and thus comparing the performance of both nomograms in 
these cohorts is not optimal. The APGI pre-operative nomogram, however, utilizes less 
variables and all are obtainable prior to surgical resection to aid decision making. 
Finally, as a proof-of-concept, biomarker expression status was assessed using 
immunohistochemical staining of the EUS-FNA cell blocks.  
 
However, due to the retrospective nature of the study, and the cohorts acquired 
were mature, with long term follow up, there are a few limitations with the study. 
First, a proportion of the recurrence pattern data were not available, therefore, 
the association between recurrence patterns and biomarker expression was not 
assessed. Secondly, pre-operative CA19-9 measurements were not available for 
a significant proportion of the patients. Increased serum levels of CA19-9 has 
been shown to be associated with early recurrence, and may improve the 
performance of a pre-operative nomogram.41 Thirdly, only a small number of pre-
operative EUS samples had sufficient material available for comparison with 
post-operative S100A2 and S100A4 immunostaining. Therefore, in order to 
further validate the clinical utility of the pre-operative nomogram, its use should 
be tested in parallel with trials in PDAC comparing upfront resection and 
Dreyer et al  Page 18 of 24 
neoadjuvant therapy. Finally, this study was not powered nor designed to 
assess S100A2 and S100A4 expression and response to adjuvant 
chemotherapy. Chemotherapy response in the adjuvant setting is difficult to 
reliably assess as survival difference is dependent on many factors including 
residual occult metastatic disease and performance status, requiring multi-
center personalized medicine trials (such as PRECISION-Panc in the UK and 
Precision Promise in the USA) to further delineate this relationship. 
Interestingly, in the APGI cohort, patients with both biomarkers positive were 
less likely to be administered adjuvant therapy, possibly due to an aggressive 
disease phenotype leading to more early recurrence and declining performance 
status and subsequently reduced adjuvant chemotherapy use. 
 
Aberrant S100A2 and S100A4 expression correlated to the recently described poor 
prognosis ‘squamous’ (also termed QM or Basal)21, 22 subtype of PDAC, which is 
enriched for transcriptional programs associated with proliferation, inflammation and 
metastasis.20 Mechanistically, S100A2 hypomethylation and associated 
increased expression is a feature of the squamous subtype. The regulation of 
S100A4 expression is more complex, potentially involving both tumour and 
microenvironment factors, and will  require further investigation.43 Interestingly, 
the squamous subtype was associated with a higher mean nomogram score and 
demonstrates the potential clinical utility of the currently presented molecular 
prognostic nomogram in identifying patients with aggressive tumor biology and a pro-
metastatic phenotype. These patients are at high risk of early recurrence and are 
unlikely to benefit from pancreatectomy and are perhaps better treated with 
neoadjuvant therapy (an increasingly popular approach to PDAC in many centers), as 
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occult metastatic disease that is not detected by current staging modalities will likely 
manifest itself during this period. However, the use of neoadjuvant therapy is not 
universal and a significant proportion of patients may not respond to this 
approach.44 Thus, patients predicted to have a favorable prognosis, may be 
better served with upfront surgery and adjuvant therapy with median survival up 
to 54 months reported using adjuvant modified FOLFIRINOX in patient cohorts 
with favorable post-operative prognostic features.45 Furthermore, the growing 
interest in more aggressive and extensive surgery in the setting of borderline 
resectable or locally advanced disease could be justified by prognostic indicators 
prior to initiating therapy.39,40 Accurate prognostication can assist multidisciplinary 
and shared decision-making, especially in patients with borderline fitness for surgery, 
which is a significant proportion of patients with PDAC, delivering a more personalized 
treatment plan. This approach has the potential to improve the overall outcomes and 
quality of life for patients with PDAC. 
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Figure Legends  
Figure 1. Methodology for biomarker validation and Nomogram construction and 
validation. A. The expression of biomarkers S100A2 and A4 was determined using 
immunohistochemistry in 3 independent cohorts of PDAC and correlated with survival 
after pancreatectomy. Biomarker expression prevalence is presented as individual pie 
charts. B and C. Survival following pancreatectomy for all 3 cohorts (b) individually and 
(c) combined, stratified by biomarker expression (both negative, one positive, both 
positive), is represented by Kaplan-Meier survival curves. Patients with both 
biomarkers positive had a survival rate of only 54%, 26% and 6% at 1, 2 and 5 years 
respectively. This was found to be 79%, 54% and 18% in the biomarker negative and 
66%, 38% and 14% in the single biomarker positive groups respectively. D. 
Clinicopathological variables for all 3 cohorts were independently entered into the 
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MSKCC post-operative nomogram to validate its performance in the patient cohorts. 
The MSKCC nomogram predicted survival in the APGI (P = 5.0 x 10-5) and Glasgow 
cohorts (P = 0.025) (green), but not the German cohort (P = 0.31) (red). E. The APGI 
training cohort was used to construct two Cox proportional hazard models, one was 
termed the APGI post-operative prognostic nomogram, and one the APGI pre-
operative prognostic nomogram. These were assessed and validated against the 
Glasgow (P = 1.7 x 10-3) and German (P = 1.2 x 10-5) validation cohorts with excellent 
fit in both cohorts. 
 
Figure 2: Kaplan-Meier survival curves for S100A2 expression in the (A) APGI, (B) 
Glasgow, (C) German cohorts; S100A4 expression in (D) APGI, (E) Glasgow, (F) 
German Cohorts. 
 
Figure 3: High S100A2 and positive S100A4 expression correlates with the squamous 
sub-type of PDAC. Patients are ranked according to S100A2 mRNA expression and 
the relative expression Z-score is represented by a waterfall plot, IHC staining and 
Bailey subtype is shown below. High S100A2 and positive S100A4 expression 
associated strongly with the squamous subtype (P < 0.001).  
 
Figure 4: A pre-operative molecular prognostic nomogram for resectable pancreatic 
cancer.  
 
Figure 5: Immunohistochemistry of EUS-FNA versus resection specimen in 2 patients  
